Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ozari Health vs Ro

Ozari Health
Graded #136

Lower grade

vs+11.299999999999997
Ro
Graded #38

Higher grade

The verdict

Ro takes it — 80.2/100 to 68.9/100.

Ro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A heavyweight platform with brand-name access — but opaque compounded pricing drags its score.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOzari Health +7
75
68
Dose & formulationRo +22
64
86
Clinical oversightRo +7
79
86
Labs & monitoringRo +30
52
82
FulfillmentRo +1
83
84
Contract termsRo +33
47
80
Ozari Health · left barRo · right bar

The numbers

MetricOzari HealthRo
WeighScore68.9/10080.2/100
GradeCB−
Scorecard rank#136#38
Semaglutide$86/mo (3-mo starter plan, new patients only, compounded)Not disclosed
Tirzepatide$125/mo (3-mo starter plan, new patients only, compounded)Not disclosed
CoverageAll 50 statesMulti-state
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Ozari Health

Graded #136 · C

Strengths

  • Very low entry pricing — compounded semaglutide from $86/month
  • LegitScript certified and operated by a named entity (Ozari LLC)
  • Board-certified physicians; meds compounded in 503A and 503B facilities
  • Shipping included in the plan price

Where it loses points

  • The advertised rates are three-month starter plans for first-time GLP-1 users, billed $257 and $375 up front; month-to-month is $175 and $235
  • Cancelling an annual or semi-annual plan early re-prices the installments already shipped at the standard monthly rate and charges the difference
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
Ro

Graded #38 · B−

Strengths

  • Brand-name access + insurance support
  • Oral options
  • Well-funded platform

Where it loses points

  • Does not disclose compounded pricing up front
  • Premium positioning

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard